The reliability of LDL-C as a short-term endpoint for a long-term disease such as cardiovascular disease lacks utility for clinicians when compared to other endpoints such as serum lipoprotein(a) and apolipoprotein B, or plaque regression endpoints such as atheroma volume reductions. The gene discussed is APOB; the disease is cardiovascular disorder.